昭衍新药
(603127)
| 流通市值：251.65亿 | | | 总市值：300.41亿 |
| 流通股本：6.28亿 | | | 总股本：7.49亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,187,905,975.28 | 703,819,032.13 | 316,135,036.49 | 1,657,624,302.72 |
| 营业收入 | 1,187,905,975.28 | 703,819,032.13 | 316,135,036.49 | 1,657,624,302.72 |
| 二、营业总成本 | 1,128,452,346.98 | 712,008,600.24 | 334,230,289.38 | 1,663,214,563.55 |
| 营业成本 | 861,829,278.83 | 536,598,243.01 | 251,371,799.79 | 1,314,312,169.51 |
| 税金及附加 | 12,854,874.81 | 8,508,374.6 | 3,174,052.51 | 9,102,383.87 |
| 销售费用 | 23,889,353.24 | 16,192,094.02 | 6,152,098.01 | 36,911,659.9 |
| 管理费用 | 203,158,553.51 | 131,866,654.26 | 66,884,931.44 | 282,261,376.13 |
| 研发费用 | 66,570,157.02 | 42,449,085.18 | 19,463,677.91 | 87,428,942.37 |
| 财务费用 | -39,849,870.43 | -23,605,850.83 | -12,816,270.28 | -66,801,968.23 |
| 其中:利息费用 | 842,664.76 | 614,445.96 | 273,931.51 | 1,421,665.35 |
| 其中:利息收入 | 55,258,242.87 | 36,875,983.46 | 19,763,775.49 | 78,186,727.67 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 971,477,536.6 | 838,035,702.05 | 283,025,818.05 | 447,560,334.54 |
| 加:投资收益 | 9,464,090.4 | 5,584,385.22 | 4,570,742.76 | 18,013,906.02 |
| 资产处置收益 | 29,488.58 | - | -20.32 | 413,517.67 |
| 资产减值损失(新) | -23,580,709.79 | -20,145,063.73 | -13,705,381.87 | -156,760,636.98 |
| 信用减值损失(新) | -9,104,318.28 | -6,318,193.75 | -2,704,427.75 | 4,086,291.11 |
| 其他收益 | 10,518,673.23 | 6,332,771.18 | 2,827,960.3 | 30,267,966.34 |
| 四、营业利润 | 1,018,258,389.04 | 815,300,032.86 | 255,919,438.28 | 337,991,117.87 |
| 加:营业外收入 | 323,731.71 | 264,121.92 | 248,474.79 | 405,289.63 |
| 减:营业外支出 | 423,493.78 | 320,996.84 | 112,521.39 | 903,142.53 |
| 五、利润总额 | 1,018,158,626.97 | 815,243,157.94 | 256,055,391.68 | 337,493,264.97 |
| 减:所得税费用 | 88,470,296.97 | 67,724,366.91 | 17,703,970.15 | 39,650,738.67 |
| 六、净利润 | 929,688,330 | 747,518,791.03 | 238,351,421.53 | 297,842,526.3 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 929,688,330 | 747,518,791.03 | 238,351,421.53 | 297,842,526.3 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 929,686,958.53 | 747,517,433.01 | 238,356,654.58 | 297,841,047.52 |
| 少数股东损益 | 1,371.47 | 1,358.02 | -5,233.05 | 1,478.78 |
| 扣除非经常损益后的净利润 | 880,951,365.34 | 698,869,735.71 | 217,391,315.27 | 311,475,492.83 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.25 | 1 | 0.32 | 0.4 |
| (二)稀释每股收益 | 1.24 | 1 | 0.32 | 0.4 |
| 八、其他综合收益 | -17,158,597.14 | -12,948,683.47 | -6,579,713.78 | -19,287,775 |
| 归属于母公司股东的其他综合收益 | -17,158,597.14 | -12,948,683.47 | -6,579,713.78 | -19,287,775 |
| 九、综合收益总额 | 912,529,732.86 | 734,570,107.56 | 231,771,707.75 | 278,554,751.3 |
| 归属于母公司股东的综合收益总额 | 912,528,361.39 | 734,568,749.54 | 231,776,940.8 | 278,553,272.52 |
| 归属于少数股东的综合收益总额 | 1,371.47 | 1,358.02 | -5,233.05 | 1,478.78 |
| 公告日期 | 2026-10-29 | 2026-08-29 | 2026-04-30 | 2026-03-31 |
| 审计意见(境内) | | | | 标准无保留意见 |